CARLSMED, INC. (CARL) — Current Report

AI-Powered SEC Filing Analysis

Latest Current Report Filed: 2026-05-05

Key Insights

Carlsmed issued Q1 2026 earnings results on May 5, 2026, with the full press release attached as Exhibit 99.1, though specific financial metrics are not disclosed in this 8-K filing itself.
The company is classified as an emerging growth company and has elected not to use the extended transition period for new accounting standards, suggesting faster adoption of regulatory changes.
Michael Cordonnier signed as CEO and President, indicating stable leadership at the company as of the filing date.

Want the newest filings?

This analysis covers the filing from 2026-05-05. New 10-K, 10-Q and 8-K filings are analyzed the moment they are released — exclusively in the app.

Download on the App Store Open in app →

Earlier Current Report filings

Filed: 2026-02-25

Carlsmed, Inc. reported its Q4 and fiscal year 2025 financial results, indicating the company's performance for the year.
The filing indicates that Carlsmed is an emerging growth company, which suggests it may be in the early stages of development.
The company's trading symbol is CARL, and it is listed on the Nasdaq Stock Market, providing investors with a public market to trade the stock.

Filed: 2026-01-12

Carlsmed, Inc. reported preliminary and unaudited revenue for the year ended December 31, 2025, indicating potential financial performance for the period.
The company is an emerging growth company, which may provide additional flexibility in financial reporting and accounting standards.
Investors should closely monitor any future press releases or financial reports from Carlsmed, Inc. to assess the company's overall performance and outlook.

Other reports for CARLSMED, INC.

Quarterly Report Insider Trading Annual Report

Important Information

AI-generated analysis is for informational purposes only. Always read original SEC filings and consult with qualified professionals before making investment decisions.